论文部分内容阅读
目的:探讨妇科肿瘤年轻患者化疗后骨密度变化的特点,为临床预防化疗后骨质疏松提供基础。方法:接受化疗的妇科恶性肿瘤年轻患者共23例,均≤40岁,根据年龄分为≤26岁组和>26岁组。分别测定其腰椎正位、股骨近端以及前臂骨密度值,同时测定其血清激素水平及血镁、钙、磷离子水平。结果:(1)23例患者中骨密度减少发生率为43.5%,其中≤26岁组9例患者中骨密度减少6例(66.7%,6/9),>26岁组14例患者中骨密度减少4例(28.6%,4/14)。≤26岁组腰椎L1～L4 BMD值明显低于>26岁组(P<0.05);(2)单纯化疗组及联合放疗组患者骨密度减少发生率的差异无统计学意义;(3)两组患者LH、FSH水平差异有统计学意义(P<0.05),其余激素以及电解质水平差异均无统计学意义。结论:妇科恶性肿瘤年轻患者化疗期间易发生骨密度减少,甚至有发生骨质疏松的可能。应重视其防治研究,对提高年轻肿瘤患者生活质量有重要意义。
Objective: To investigate the characteristics of bone mineral density (BMD) in young patients with gynecologic oncology after chemotherapy and provide the basis for clinical prevention of osteoporosis after chemotherapy. Methods: A total of 23 young patients with gynecological malignancy who underwent chemotherapy were ≤40 years old, divided into groups of ≤26 years and> 26 years according to their age. The lumbar spine, proximal femur and forearm bone mineral density (BMD) were measured respectively. The level of serum hormone and the level of serum magnesium, calcium and phosphorus were also determined. Results: (1) The incidence of bone mineral density (BMD) reduction was 43.5% in 23 patients, 6 patients (66.7%, 6/9) in 9 patients ≤26 years old and 14 patients> 26 years old Decreased density in 4 cases (28.6%, 4/14). The BMD of L1 ~ L4 in lumbar vertebra≤26 years old group was significantly lower than that of> 26 years old group (P <0.05); (2) There was no significant difference in the BMD of patients between chemotherapy group and radiotherapy group; (3) There were significant differences in LH and FSH levels between the two groups (P <0.05), while the levels of other hormones and electrolytes were not significantly different. Conclusion: Young patients with gynecologic malignancies tend to have decreased BMD during chemotherapy and may even have osteoporosis. Should pay attention to its prevention and treatment research, to improve the quality of life of young patients with cancer is of great significance.